1.Therapeutic Impact on Quality of Life in Adult Patients With Chronic Intestinal Pseudo-obstruction: A Multicenter, Cohort Study
Kota TAKAHASHI ; Takaomi KESSOKU ; Hidenori OHKUBO ; Yo ISHIHARA ; Kosuke TANAKA ; Tomoki OGATA ; Tsumugi JONO ; Atsushi YAMAMOTO ; Anna OZAKI ; Yuki KASAI ; Michihiro IWAKI ; Akiko FUYUKI ; Takayuki KATO ; Yasunari SAKAMOTO ; Takeo KURIHASHI ; Hirotoshi EBINUMA ; Atsushi NAKAJIMA
Journal of Neurogastroenterology and Motility 2026;32(2):244-253
Background/Aims:
To evaluate the quality of life (QOL) of patients with chronic intestinal pseudo-obstruction (CIPO) before and after treatment.
Methods:
This study enrolled 50 adult patients diagnosed with CIPO at 4 institutions, of whom 42 underwent therapy.Patient background, body mass index, treatment, palliative care intervention, numerical rating scale for abdominal pain or bloating, the medical outcomes study 36-item short-form health survey (SF-36) and summary scores (physical component summary, mental component summary, and role/social component summary), Japanese version of the Patient Assessment of Constipation Quality of Life (JPAC-QOL) and subscales (physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction), and Patient Assessment of Constipation Symptoms (PAC-SYM) and subscales (stool, rectal, and abdominal symptoms) were prospectively sampled and collected.
Results:
The patients (n = 50; 35 females and 15 males) had an average age of onset of 44.7 years and, body mass index of 17.3 kg/m², and 38 (76%) required palliative care intervention. Effective therapeutic interventions included intestinal sterilization (19/42), decompression therapy with percutaneous endoscopic gastrojejunostomy (PEG-J) (6/42), and dietary restriction (6/42). The numerical rating scale for abdominal distension and pain decreased significantly after treatment. All SF-36 summary scores showed improvements. The JPAC-QOL and PAC-SYM both showed improvement overall and in all subscales.
Conclusions
Patients with CIPO have a lower physical, psychological and social QOL, which is equivalent to or lower than that of adult patients with inflammatory bowel disease or psychiatric disorders. Sterilization of the intestinal tract and PEG-J decompression effectively improve the QOL of patients.
2.Catastrophic Rebleeding during Woven EndoBridge Treatment of a Large Ruptured Internal Carotid Artery Aneurysm with a Fetal-Type Posterior Communicating Artery: A Case Report
Koki TANAKA ; Ichiro NAKAHARA ; Kosuke KAKUMOTO ; Daichi BABA ; Shigenari KIN
Neurointervention 2026;21(2):136-141
Intraprocedural rupture during Woven EndoBridge (WEB) treatment is most commonly reported in the early deployment phase, whereas rebleeding after substantial deployment is considered rare. We report a patient in their early 90s with poor-grade subarachnoid hemorrhage caused by a large ruptured internal carotid artery aneurysm with a fetal-type posterior communicating artery. After initial deployment, the bleb was already covered by the lateral surface of the device. During partial resheathing and repositioning to preserve the branch, the WEB rotated slightly, altering the configuration of the device relative to the bleb and thereby changing device–aneurysm wall interaction. Retrospective assessment of the procedural recording later suggested minimal contrast leakage just above the bleb, although massive hemorrhage became evident only during the final angiographic runs after detachment. Rescue treatment with balloon occlusion and n-butyl cyanoacrylate embolization achieved hemostasis; however, postprocedural cone-beam computed tomography revealed a massive intracerebral hematoma, and the patient died 3 days later despite supportive care. This case underscores that even after substantial deployment, repositioning maneuvers may carry a risk under specific high-risk conditions.
3.Impact of Stroke Severity and Vascular Risk Factors on Early Versus Late Anticoagulation in Patients With Stroke and Atrial Fibrillation
Masatoshi KOGA ; Mattia BRANCA ; Daniel STRBIAN ; Takeshi YOSHIMOTO ; Kanta TANAKA ; Sohei YOSHIMURA ; Yusuke YAKUSHIJI ; Shigeru FUJIMOTO ; Adhiyaman VEDAMURTHY ; Manju KRISHNAN ; Marjaana TIAINEN ; Jochen VEHOFF ; Gerli SIBOLT ; Kosuke MATSUZONO ; Caterina KULYK ; Silja RÄTY ; Peter SLADE ; Alexander SALERNO ; Dimitri HEMELSOET ; Thomas HORVATH ; Takenobu KUNIEDA ; Makoto NAKAJIMA ; Hisanao AKIYAMA ; Yasuyuki IGUCHI ; Manabu INOUE ; Masafumi IHARA ; Kazunori TOYODA ; David SEIFFGE ; Martina GOELDLIN ; Jesse DAWSON ; Urs FISCHER
Journal of Stroke 2025;27(2):284-288
4.Impact of Stroke Severity and Vascular Risk Factors on Early Versus Late Anticoagulation in Patients With Stroke and Atrial Fibrillation
Masatoshi KOGA ; Mattia BRANCA ; Daniel STRBIAN ; Takeshi YOSHIMOTO ; Kanta TANAKA ; Sohei YOSHIMURA ; Yusuke YAKUSHIJI ; Shigeru FUJIMOTO ; Adhiyaman VEDAMURTHY ; Manju KRISHNAN ; Marjaana TIAINEN ; Jochen VEHOFF ; Gerli SIBOLT ; Kosuke MATSUZONO ; Caterina KULYK ; Silja RÄTY ; Peter SLADE ; Alexander SALERNO ; Dimitri HEMELSOET ; Thomas HORVATH ; Takenobu KUNIEDA ; Makoto NAKAJIMA ; Hisanao AKIYAMA ; Yasuyuki IGUCHI ; Manabu INOUE ; Masafumi IHARA ; Kazunori TOYODA ; David SEIFFGE ; Martina GOELDLIN ; Jesse DAWSON ; Urs FISCHER
Journal of Stroke 2025;27(2):284-288
5.Impact of Stroke Severity and Vascular Risk Factors on Early Versus Late Anticoagulation in Patients With Stroke and Atrial Fibrillation
Masatoshi KOGA ; Mattia BRANCA ; Daniel STRBIAN ; Takeshi YOSHIMOTO ; Kanta TANAKA ; Sohei YOSHIMURA ; Yusuke YAKUSHIJI ; Shigeru FUJIMOTO ; Adhiyaman VEDAMURTHY ; Manju KRISHNAN ; Marjaana TIAINEN ; Jochen VEHOFF ; Gerli SIBOLT ; Kosuke MATSUZONO ; Caterina KULYK ; Silja RÄTY ; Peter SLADE ; Alexander SALERNO ; Dimitri HEMELSOET ; Thomas HORVATH ; Takenobu KUNIEDA ; Makoto NAKAJIMA ; Hisanao AKIYAMA ; Yasuyuki IGUCHI ; Manabu INOUE ; Masafumi IHARA ; Kazunori TOYODA ; David SEIFFGE ; Martina GOELDLIN ; Jesse DAWSON ; Urs FISCHER
Journal of Stroke 2025;27(2):284-288
6.Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma:a multicenter retrospective analysis
Shinichi TATE ; Toshiyuki SEKI ; Kyoko NISHIKIMI ; Youichi UNNO ; Mizue ITOI ; Sadatomo IKEDA ; Nobuhisa YOSHIKAWA ; Hidehiko AKASHI ; Eitaro SUZUKI ; Naotake TANAKA ; Takashi HIRAKAWA ; Hiroaki KAJIYAMA ; Hirokuni TAKANO ; Kosuke YOSHIHARA ; Kaori KOGA ; Aikou OKAMOTO ; Makio SHOZU
Journal of Gynecologic Oncology 2025;36(5):e80-
Objective:
Advanced ovarian clear cell carcinoma (OCCC) is associated with poor outcomes owing to chemoresistance. Bevacizumab (Bev) is increasingly being used to treat advanced ovarian cancer; however, its efficacy in OCCC remains unclear. This study evaluated the treatment outcomes of frontline bevacizumab chemotherapy in patients with OCCC.
Methods:
This retrospective multi-institutional study included patients diagnosed with advanced OCCC at eight institutions in Japan between 2008 and 2018. Patients were categorized into pre and post-market groups based on the Bev approval dates. Progressionfree survival (PFS) and overall survival (OS) were analyzed using univariate and multivariate methods. Additionally, patients were classified into Bev-treated (Bev+) and non-Bev-treated (Bev−) groups, and their prognoses were compared.
Results:
A total of 96 patients were in the pre-market group and 82 in the post-market group. The post-market group had a significantly higher proportion of patients with poor performance status and patients who underwent interval debulking surgery (p<0.01 and p<0.01, respectively). Univariate analysis demonstrated a better PFS in the post-market group (p=0.041). In multivariate analysis, better PFS (hazard ratio [HR]=0.52; p=0.002) and OS (HR=0.47; p=0.002) were observed in the post-market group than in the pre-market group.Bev+ patients had significantly better PFS and OS than Bev− patients in univariate (p<0.001 and p<0.001, respectively) and multivariate analyses (PFS: HR=0.36; p<0.001 and OS:HR=0.21; p=0.001, respectively).
Conclusion
Incorporating Bev into frontline chemotherapy may improve outcomes in patients with advanced OCCC.
7.Mucosal and Submucosal Thickening of Esophageal Wall Is a Promising Factor in the Development of Symptoms in Eosinophilic Esophagitis
Yugo SUZUKI ; Yorinari OCHIAI ; Atsuko HOSOI ; Takayuki OKAMURA ; Junnosuke HAYASAKA ; Yutaka MITSUNAGA ; Masami TANAKA ; Hiroyuki ODAGIRI ; Kosuke NOMURA ; Satoshi YAMASHITA ; Akira MATSUI ; Daisuke KIKUCHI ; Kenichi OHASHI ; Shu HOTEYA
Gut and Liver 2024;18(1):50-59
Background/Aims:
Asymptomatic esophageal eosinophilia (aEE) is considered to be a potential precursor of eosinophilic esophagitis (EoE). However, there are few clinical parameters that can be used to evaluate the disease. Therefore, we aimed to clarify the factors involved in the symptoms of EoE by examining the clinicopathological differences between aEE and EoE.
Methods:
We reviewed 41 patients with esophageal eosinophilia who underwent endoscopic ultrasonography and high-resolution manometry. They were divided into the aEE group (n=16) and the EoE group (n=25) using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease score. The patients’ clinicopathological findings were collected and examined.
Results:
The median Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease score was 3.0 in the aEE group and 10.0 in the EoE group. There was no significant difference in patient characteristics, endoscopic findings and pathological findings. The cutoff value for wall thickening was 3.13 mm for the total esophageal wall thickness and 2.30 mm for the thickness from the surface to the muscular layer (total esophageal wall thickness: 84.0% sensitivity, 75.0% specificity; thickness from the surface to the muscular layer: 84.0% sensitivity, 68.7% specificity).The high-resolution manometry study was abnormal in seven patients (43.8%) in the aEE group and in 12 (48.0%) in the EoE group. The contractile front velocity was slower in the EoE group (p=0.026).
Conclusions
The esophageal wall thickening in the lower portion of the esophagus is an important clinical factors related to the symptoms in patients with EoE.
8.The Prevalence and Characteristics of Symptomatic Uncomplicated Diverticular Disease Among Asian Patients With Unexplained Abdominal Symptoms
Tsumugi JONO ; Yuki KASAI ; Takaomi KESSOKU ; Tomoki OGATA ; Kosuke TANAKA ; Tsutomu YOSHIHARA ; Noboru MISAWA ; Shingo KATO ; Takuma HIGURASHI ; Kunihiro HOSONO ; Masato YONEDA ; Kosuke SEITA ; Takayuki KATO ; Eiji SAKAI ; Takeo KURIHASHI ; Machiko NAKATOGAWA ; Shunsuke OYAMADA ; Seiji FUTAGAMI ; Kok-Ann GWEE ; Atsushi NAKAJIMA
Journal of Neurogastroenterology and Motility 2024;30(1):87-96
Background/Aims:
The precise incidence of symptomatic uncomplicated diverticular disease (SUDD) and its effects on the quality of life (QOL) remain unclear, particularly in Asian patients with right-sided SUDD. We assess the prevalence of SUDD and its impact on QOL in a real-world population.
Methods:
Five institutional cohorts of patients who received outpatient treatment for unexplained abdominal symptoms from January 15, 2020 to March 31, 2022, were included. All patients underwent colonoscopy. SUDD was defined as the presence of recurrent abdominal symptoms, particularly pain in the lower right or left quadrant lasting > 24 hours in patients with diverticulosis at the site of pain. The 36-item short-form health survey was used to assess QOL.
Results:
Diverticula were identified in 108 of 361 patients. Among these 108 patients, 31% had SUDD, which was right-sided in 39% of cases.Of the 50 patients with right-sided diverticula, 36% had SUDD, as did 15 of 35 patients with left-sided diverticula (43%). Among the 33 patients with SUDD, diverticula were right-sided, left-sided, and bilateral in 39%, 45%, and 15% of patients, respectively. Diarrhea was more frequent in the SUDD group than in the non-SUDD group. Patients with SUDD had significantly lower physical, mental, and role/social component scores than those without SUDD.
Conclusions
It is important to recognize that patients with SUDD account for as high as 31% of outpatients with unexplained abdominal symptoms; these patients have diarrhea and a low QOL. The presence of right-sided SUDD was characteristic of Asian patients.
9.Natural History of Chronic Intestinal Pseudo-obstruction and Need for Palliative Care
Kosuke TANAKA ; Hidenori OHKUBO ; Atsushi YAMAMOTO ; Kota TAKAHASHI ; Yuki KASAI ; Anna OZAKI ; Michihiro IWAKI ; Takashi KOBAYASHI ; Tsutomu YOSHIHARA ; Noboru MISAWA ; Akiko FUYUKI ; Shingo KATO ; Takuma HIGURASHI ; Kunihiro HOSONO ; Masato YONEDA ; Takeo KURIHASHI ; Masataka TAGURI ; Atsushi NAKAJIMA ; Kok-Ann GWEE ; Takaomi KESSOKU
Journal of Neurogastroenterology and Motility 2023;29(3):378-387
Background/Aims:
Natural history of chronic intestinal pseudo-obstruction (CIPO), a rare disease characterized by episodes of non-mechanical obstruction, is unclear in adults. This study evaluates the clinical course of CIPO and palliative care needs of patients.
Methods:
From October 2010 to September 2021, 74 patients who underwent cine MRI and had a definitive diagnosis of CIPO were prospectively included. We investigated disease etiology and outcomes, age at onset, nutritional status at consultation (body mass index and serum albumin), hydrogen breath test results, and total parenteral nutrition (TPN) during the disease course.
Results:
Forty-seven patients (64%) were women, with a mean age of 44 years at onset and 49 years at diagnosis. Primary CIPO was observed in 48 patients (65%). Secondary CIPO was observed in 26 cases (35%), of whom 18 (69%) had scleroderma. The mean body mass index, serum albumin level, and hydrogen breath test positivity rate were 17 kg/m2 , 3.8 mg/dL, and 60%, respectively. TPN and invasive decompression therapy were required by 23 (31%) and 18 (24%) patients, respectively. Intestinal sterilization was performed in 51 (69%) patients and was effective in 33 (65%); of these, 28 (85%) were taking metronidazole. Seven (9%) patients used opioids. There were 9 deaths (12%), including 5 (56%) from infection and 2 (22%) from suicide. Of the deaths, 6 (67%) and 4 (44%) underwent TPN management and decompression therapy, respectively. Fifty-one patients (69%) wanted palliative care.
Conclusion
CIPO is a rare, severe, and under-recognized disease. Standardization of treatment strategies, including palliative care and psychiatric interventions, is desired.
10.The Decocting Time and the Contents of the Aconitine-type Diester Alkaloids in the Decoctions of the Formula Containing Unprocessed Aconite Root in “Songban Shanghanlun”
Tsukasa FUEKI ; Yohei TANIMURA ; Koichiro TANAKA ; Koki CHIBA ; Takanori MATSUOKA ; Takao NAMIKI ; Kosuke FUJITA ; Takao SUNAGA ; Masashi BEPPU ; Toshiaki MAKINO
Kampo Medicine 2019;70(4):313-323
We investigated the decocting time to prepare the formulas containing unprocessed aconite root, such as shigyakuto, tsumyaku shigyakuto, and kankyobushito, which had been registered in “Shanghanlun” edited in Song Dynasty, using the weights and measures in Houhan Dynasty when the original “Shanghanlun” was regarded to have been established. Also the contents of aconitine-type diester alkaloids (ADA) eluted from unprocessed aconite root in the decoction were analyzed in time-dependent manners. As regards the modified formula for the “physically strong patients” in the texts of tsumyakushigyakuto in “Shanghanlun”, adding dried ginger was found to lead the decocting time to be shorter and the sum of ADA content in the decoction of the modified formula to increase about 20%. It was also found that the compositions of diterpene alkaloids derived from aconite root in kankyobushito decoction were highly different from those in shigyakuto decoction, containing less ADA and more aconine and hypaconine, due to the high pH of the decoction, which was the consequence of lacking glycyrrhiza in kankyobushito formula. It is suggested that the doctors in the era of “Shanghanlun” establishment may have carefully adjusted the contents of ADA in the decoctions using unprocessed aconite root by choosing co-decocted crude drugs.


Result Analysis
Print
Save
E-mail